{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:32:01Z","timestamp":1794933121695,"version":"4.9.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-62506-2","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T17:00:24Z","timestamp":1754326824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9610-9240","authenticated-orcid":false,"given":"Yuchen","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3618-8749","authenticated-orcid":false,"given":"Tianchuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6135-357X","authenticated-orcid":false,"given":"Zhenxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-8390","authenticated-orcid":false,"given":"Xi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"62506_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"62506_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.semcancer.2022.10.006","volume":"87","author":"M Castaneda","year":"2022","unstructured":"Castaneda, M., den Hollander, P., Kuburich, N. A., Rosen, J. M. & Mani, S. A. Mechanisms of cancer metastasis. Semin. Cancer Biol. 87, 17\u201331 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"62506_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","volume":"27","author":"K Ganesh","year":"2021","unstructured":"Ganesh, K. & Massague, J. Targeting metastatic cancer. Nat. Med. 27, 34\u201344 (2021).","journal-title":"Nat. Med."},{"key":"62506_CR4","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/s41551-021-00712-1","volume":"5","author":"Q Hu","year":"2021","unstructured":"Hu, Q. et al. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. Nat. Biomed. Eng. 5, 1038\u20131047 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"62506_CR5","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell 186, 1564\u20131579 (2023).","journal-title":"Cell"},{"key":"62506_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22, 20 (2023).","journal-title":"Mol. Cancer"},{"key":"62506_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang, P., Zhang, G. & Wan, X. Challenges and new technologies in adoptive cell therapy. J. Hematol. Oncol. 16, 97 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"62506_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.it.2022.10.002","volume":"43","author":"LM Sly","year":"2022","unstructured":"Sly, L. M. & McKay, D. M. Macrophage immunotherapy: overcoming impediments to realize promise. Trends Immunol. 43, 959\u2013968 (2022).","journal-title":"Trends Immunol."},{"key":"62506_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-022-01328-x","volume":"15","author":"W Li","year":"2022","unstructured":"Li, W., Wang, F., Guo, R., Bian, Z. & Song, Y. Targeting macrophages in hematological malignancies: recent advances and future directions. J. Hematol. Oncol. 15, 110 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"62506_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei, A. et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat. Immunol. 25, 102\u2013116 (2024).","journal-title":"Nat. Immunol."},{"key":"62506_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"62506_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","volume":"13","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J. Hematol. Oncol. 13, 153 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"62506_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41470-9","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors. Nat. Commun. 14, 5778 (2023).","journal-title":"Nat. Commun."},{"key":"62506_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01735-9","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu, Q. et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol. Cancer 22, 28 (2023).","journal-title":"Mol. Cancer"},{"key":"62506_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan, K. et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J. Exp. Clin. Cancer Res. 41, 119 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"62506_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111605","volume":"139","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. CAR-macrophage: a new immunotherapy candidate against solid tumors. Biomed. Pharmacother. 139, 111605 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"62506_CR17","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","volume":"185","author":"A Raguram","year":"2022","unstructured":"Raguram, A., Banskota, S. & Liu, D. R. Therapeutic in vivo delivery of gene editing agents. Cell 185, 2806\u20132827 (2022).","journal-title":"Cell"},{"key":"62506_CR18","doi-asserted-by":"crossref","unstructured":"Hamilton, J. R. et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat. Biotechnol. 42, 1684\u20131692 (2024).","DOI":"10.1038\/s41587-023-02085-z"},{"key":"62506_CR19","doi-asserted-by":"crossref","unstructured":"Nie, S., Qin, Y., Ou, L., Chen, X. & Li, L. In situ reprogramming of immune cells using synthetic nanomaterials. Adv. Mater. 36, e2310168 (2024).","DOI":"10.1002\/adma.202310168"},{"key":"62506_CR20","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.ymthe.2022.05.018","volume":"30","author":"A Michels","year":"2022","unstructured":"Michels, A., Ho, N. & Buchholz, C. J. Precision medicine: in vivo CAR therapy as a showcase for receptor-targeted vector platforms. Mol. Ther. 30, 2401\u20132415 (2022).","journal-title":"Mol. Ther."},{"key":"62506_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1165576","volume":"14","author":"YT Qin","year":"2023","unstructured":"Qin, Y. T. et al. Biomaterials promote in vivo generation and immunotherapy of CAR-T cells. Front. Immunol. 14, 1165576 (2023).","journal-title":"Front. Immunol."},{"key":"62506_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz, W. et al. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J. 11, 119 (2021).","journal-title":"Blood Cancer J."},{"key":"62506_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"62506_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-bioeng-070620-033348","volume":"23","author":"NN Parayath","year":"2021","unstructured":"Parayath, N. N. & Stephan, M. T. In situ programming of CAR T cells. Annu. Rev. Biomed. Eng. 23, 385\u2013405 (2021).","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"62506_CR25","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nnano.2017.57","volume":"12","author":"TT Smith","year":"2017","unstructured":"Smith, T. T. et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat. Nanotechnol. 12, 813\u2013820 (2017).","journal-title":"Nat. Nanotechnol."},{"key":"62506_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"62506_CR27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","volume":"23","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526\u2013543 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"62506_CR28","doi-asserted-by":"crossref","unstructured":"Wu, J., Wu, W., Zhou, B. & Li, B. Chimeric antigen receptor therapy meets mRNA technology. Trends Biotechnol. 42, 228\u2013240 (2023).","DOI":"10.1016\/j.tibtech.2023.08.005"},{"key":"62506_CR29","doi-asserted-by":"crossref","unstructured":"Huang, P., Deng, H., Wang, C., Zhou, Y. & Chen, X. Cellular trafficking of nanotechnology-mediated mRNA delivery. Adv. Mater. 36, e2307822 (2024).","DOI":"10.1002\/adma.202307822"},{"key":"62506_CR30","doi-asserted-by":"crossref","unstructured":"Zong, Y., Lin, Y., Wei, T., & Cheng, Q. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy. Adv. Mater. 35, e2303261 (2023).","DOI":"10.1002\/adma.202303261"},{"key":"62506_CR31","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-020-00261-0","volume":"5","author":"J Dai","year":"2020","unstructured":"Dai, J. et al. Exosomes: key players in cancer and potential therapeutic strategy. Signal Transduct. Target. Ther. 5, 145 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"62506_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01472-z","volume":"20","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Recent advances in exosome-mediated nucleic acid delivery for cancer therapy. J. Nanobiotechnology 20, 279 (2022).","journal-title":"J. Nanobiotechnology"},{"key":"62506_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","volume":"14","author":"Z Cheng","year":"2021","unstructured":"Cheng, Z., Li, M., Dey, R. & Chen, Y. Nanomaterials for cancer therapy: current progress and perspectives. J. Hematol. Oncol. 14, 85 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"62506_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrd3978","volume":"12","author":"SELA Mager","year":"2013","unstructured":"Mager, S. E. L. A., Breakefield, I. & Wood, X. O. MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12, 347\u2013357 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"62506_CR35","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh, J. A. et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J. Extracell. Vesicles 13, e12404 (2024).","journal-title":"J. Extracell. Vesicles"},{"key":"62506_CR36","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","volume":"9","author":"H Valadi","year":"2007","unstructured":"Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654\u2013659 (2007).","journal-title":"Nat. Cell Biol."},{"key":"62506_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03733-8","volume":"9","author":"R Kojima","year":"2018","unstructured":"Kojima, R. et al. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson\u2019s disease treatment. Nat. Commun. 9, 1305 (2018).","journal-title":"Nat. Commun."},{"key":"62506_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-023-01382-y","volume":"8","author":"M Zhang","year":"2023","unstructured":"Zhang, M. et al. Engineered exosomes from different sources for cancer-targeted therapy. Signal Transduct. Target Ther. 8, 124 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"62506_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202207875","volume":"35","author":"C Zhao","year":"2023","unstructured":"Zhao, C. et al. Vesicular antibodies: shedding light on antibody therapeutics with cell membrane nanotechnology. Adv. Mater. 35, e2207875 (2023).","journal-title":"Adv. Mater."},{"key":"62506_CR40","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.ymthe.2023.02.013","volume":"31","author":"J Radler","year":"2023","unstructured":"Radler, J., Gupta, D., Zickler, A. & Andaloussi, S. E. Exploiting the biogenesis of extracellular vesicles for bioengineering and therapeutic cargo loading. Mol. Ther. 31, 1231\u20131250 (2023).","journal-title":"Mol. Ther."},{"key":"62506_CR41","doi-asserted-by":"publisher","first-page":"16770","DOI":"10.1021\/acsnano.3c03456","volume":"17","author":"T Zhu","year":"2023","unstructured":"Zhu, T., Chen, Z., Jiang, G. & Huang, X. Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-Cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy. ACS Nano 17, 16770\u201316786 (2023).","journal-title":"ACS Nano"},{"key":"62506_CR42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.actbio.2022.11.043","volume":"157","author":"Y Xiao","year":"2023","unstructured":"Xiao, Y. et al. Functionalized biomimetic nanoparticles combining programmed death-1\/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy. Acta Biomater. 157, 451\u2013466 (2023).","journal-title":"Acta Biomater."},{"key":"62506_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-01148-0","volume":"19","author":"T Zhu","year":"2021","unstructured":"Zhu, T. et al. Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19. J. Nanobiotechnology 19, 391 (2021).","journal-title":"J. Nanobiotechnology"},{"key":"62506_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202211138","volume":"35","author":"X Li","year":"2023","unstructured":"Li, X. et al. Genetically programmable vesicles for enhancing CAR-T therapy against solid tumors. Adv. Mater. 35, e2211138 (2023).","journal-title":"Adv. Mater."},{"key":"62506_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang, X., Wang, J., Lu, D. & Xu, X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct. Target Ther. 6, 75 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"62506_CR46","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","volume":"159","author":"OM Elsharkasy","year":"2020","unstructured":"Elsharkasy, O. M. et al. Extracellular vesicles as drug delivery systems: why and how?. Adv. Drug Deliv. Rev. 159, 332\u2013343 (2020).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"62506_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14344-7","volume":"11","author":"PC Dinh","year":"2020","unstructured":"Dinh, P. C. et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat. Commun. 11, 1064 (2020).","journal-title":"Nat. Commun."},{"key":"62506_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12134","volume":"10","author":"MM Shi","year":"2021","unstructured":"Shi, M. M. et al. Preclinical efficacy and clinical safety of clinical-grade nebulized allogenic adipose mesenchymal stromal cells-derived extracellular vesicles. J. Extracell. Vesicles 10, e12134 (2021).","journal-title":"J. Extracell. Vesicles"},{"key":"62506_CR49","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jconrel.2017.11.036","volume":"269","author":"HM Abdelaziz","year":"2018","unstructured":"Abdelaziz, H. M. et al. Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates. J. Control. Release 269, 374\u2013392 (2018).","journal-title":"J. Control. Release"},{"key":"62506_CR50","doi-asserted-by":"crossref","unstructured":"Liu, M., Hu, S., Yan, N., Popowski, K. D., & Cheng, K. Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity. Nat. Nanotechnol. 19, 565\u2013575 (2024).","DOI":"10.1038\/s41565-023-01580-3"},{"key":"62506_CR51","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2019.1663043","volume":"8","author":"G Corso","year":"2019","unstructured":"Corso, G. et al. Systematic characterization of extracellular vesicle sorting domains and quantification at the single molecule\u2014single vesicle level by fluorescence correlation spectroscopy and single particle imaging. J. Extracell. Vesicles 8, 1663043 (2019).","journal-title":"J. Extracell. Vesicles"},{"key":"62506_CR52","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin, Y., Xu, J. & Lan, H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J. Hematol. Oncol. 12, 76 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"62506_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-01810-9","volume":"21","author":"L Gao","year":"2023","unstructured":"Gao, L. et al. Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2\/Her2-specific CAR-macrophages for brainstem glioma immunotherapy. J. Nanobiotechnology 21, 56 (2023).","journal-title":"J. Nanobiotechnology"},{"key":"62506_CR54","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2020.1779458","volume":"9","author":"L Xu","year":"2020","unstructured":"Xu, L. et al. Design of experiment (DoE)-driven in vitro and in vivo uptake studies of exosomes for pancreatic cancer delivery enabled by copper-free click chemistry-based labelling. J. Extracell. Vesicles 9, 1779458 (2020).","journal-title":"J. Extracell. Vesicles"},{"key":"62506_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/619829","volume":"2014","author":"CA Franzen","year":"2014","unstructured":"Franzen, C. A. et al. Characterization of uptake and internalization of exosomes by bladder cancer cells. Biomed. Res. Int. 2014, 619829 (2014).","journal-title":"Biomed. Res. Int."},{"key":"62506_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202407619","volume":"11","author":"AM Zickler","year":"2024","unstructured":"Zickler, A. M. et al. Novel endogenous engineering platform for robust loading and delivery of functional mRNA by extracellular vesicles. Adv. Sci. 11, e2407619 (2024.","journal-title":"Adv. Sci."},{"key":"62506_CR57","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1021\/acs.bioconjchem.2c00307","volume":"33","author":"H Hirose","year":"2022","unstructured":"Hirose, H., Hirai, Y., Sasaki, M., Sawa, H. & Futaki, S. Quantitative analysis of extracellular vesicle uptake and fusion with recipient cells. Bioconjug. Chem. 33, 1852\u20131859 (2022).","journal-title":"Bioconjug. Chem."},{"key":"62506_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22126-y","volume":"12","author":"E Bonsergent","year":"2021","unstructured":"Bonsergent, E. et al. Quantitative characterization of extracellular vesicle uptake and content delivery within mammalian cells. Nat. Commun. 12, 1864 (2021).","journal-title":"Nat. Commun."},{"key":"62506_CR59","doi-asserted-by":"publisher","first-page":"e1009951","DOI":"10.1371\/journal.pgen.1009951","volume":"17","author":"M Albanese","year":"2021","unstructured":"Albanese, M. et al. MicroRNAs are minor constituents of extracellular vesicles that are rarely delivered to target cells. PLoS Genet. 17, e1009951 (2021).","journal-title":"PLoS Genet."},{"key":"62506_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42402-3","volume":"14","author":"CL Chiang","year":"2023","unstructured":"Chiang, C. L. et al. Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer. Nat. Commun. 14, 6692 (2023).","journal-title":"Nat. Commun."},{"key":"62506_CR61","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1993769","volume":"13","author":"S Liu","year":"2021","unstructured":"Liu, S., Verma, A., Kettenberger, H., Richter, W. F. & Shah, D. K. Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies. MAbs 13, 1993769 (2021).","journal-title":"MAbs"},{"key":"62506_CR62","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1021\/acs.molpharmaceut.1c00373","volume":"19","author":"P Gupta","year":"2022","unstructured":"Gupta, P. et al. Antibodies with weakly basic isoelectric points minimize trade-offs between formulation and physiological colloidal properties. Mol. Pharm. 19, 775\u2013787 (2022).","journal-title":"Mol. Pharm."},{"key":"62506_CR63","doi-asserted-by":"publisher","first-page":"283","DOI":"10.20517\/evcna.2023.26","volume":"4","author":"L Ribovski","year":"2023","unstructured":"Ribovski, L., Joshi, B., Gao, J. & Zuhorn, I. Breaking free: endocytosis and endosomal escape of extracellular vesicles. Extracell. Vesicles Circ. Nucl. Acids 4, 283\u2013305 (2023).","journal-title":"Extracell. Vesicles Circ. Nucl. Acids"},{"key":"62506_CR64","doi-asserted-by":"publisher","first-page":"344","DOI":"10.20517\/evcna.2024.19","volume":"5","author":"L Hagedorn","year":"2024","unstructured":"Hagedorn, L., Jurgens, D. C., Merkel, O. M. & Winkeljann, B. Endosomal escape mechanisms of extracellular vesicle-based drug carriers: lessons for lipid nanoparticle design. Extracell. Vesicles Circ. Nucl. Acids 5, 344\u2013357 (2024).","journal-title":"Extracell. Vesicles Circ. Nucl. Acids"},{"key":"62506_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12085","volume":"10","author":"M Kang","year":"2021","unstructured":"Kang, M., Jordan, V., Blenkiron, C. & Chamley, L. W. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J. Extracell. Vesicles 10, e12085 (2021).","journal-title":"J. Extracell. Vesicles"},{"key":"62506_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","volume":"22","author":"A Lahiri","year":"2023","unstructured":"Lahiri, A. et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol. Cancer 22, 40 (2023).","journal-title":"Mol. Cancer"},{"key":"62506_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang, M. et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv. Mater. 33, e2103258 (2021).","journal-title":"Adv. Mater."},{"key":"62506_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01775-1","volume":"22","author":"L Hovhannisyan","year":"2023","unstructured":"Hovhannisyan, L., Riether, C., Aebersold, D. M., Medova, M. & Zimmer, Y. CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks. Mol. Cancer 22, 82 (2023).","journal-title":"Mol. Cancer"},{"key":"62506_CR69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1128","volume":"14","author":"C Chen","year":"2022","unstructured":"Chen, C. et al. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci. Transl. Med. 14, eabn1128 (2022).","journal-title":"Sci. Transl. Med."},{"key":"62506_CR70","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","volume":"360","author":"Z Yang","year":"2023","unstructured":"Yang, Z. et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J. Control. Release 360, 718\u2013733 (2023).","journal-title":"J. Control. Release"},{"key":"62506_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25839-2","volume":"12","author":"S Shrivastava","year":"2021","unstructured":"Shrivastava, S. et al. Exosome-mediated stable epigenetic repression of HIV-1. Nat. Commun. 12, 5541 (2021).","journal-title":"Nat. Commun."},{"key":"62506_CR72","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41580-020-0251-y","volume":"21","author":"K O\u2019Brien","year":"2020","unstructured":"O\u2019Brien, K., Breyne, K., Ughetto, S., Laurent, L. C. & Breakefield, X. O. RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat. Rev. Mol. Cell Biol. 21, 585\u2013606 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"62506_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202002054","volume":"32","author":"Y Xia","year":"2020","unstructured":"Xia, Y. et al. Engineering macrophages for cancer immunotherapy and drug delivery. Adv. Mater. 32, e2002054 (2020).","journal-title":"Adv. Mater."},{"key":"62506_CR74","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.omtm.2020.02.003","volume":"17","author":"A Kunz","year":"2020","unstructured":"Kunz, A. et al. Optimized Assessment of qPCR-based vector copy numbers as a safety parameter for GMP-grade CAR T cells and monitoring of frequency in patients. Mol. Ther. Methods Clin. Dev. 17, 448\u2013454 (2020).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"62506_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101120","volume":"31","author":"J Kandell","year":"2023","unstructured":"Kandell, J., Milian, S., Snyder, R. & Lakshmipathy, U. Universal ddPCR-based assay for the determination of lentivirus infectious titer and lenti-modified cell vector copy number. Mol. Ther. Methods Clin. Dev. 31, 101120 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"62506_CR76","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-1-4939-6990-6_17","volume":"1606","author":"A Alamri","year":"2017","unstructured":"Alamri, A., Nam, J. Y. & Blancato, J. K. Fluorescence in situ hybridization of cells, chromosomes, and formalin-fixed paraffin-embedded tissues. Methods Mol. Biol. 1606, 265\u2013279 (2017).","journal-title":"Methods Mol. Biol."},{"key":"62506_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-2-3","volume":"2","author":"L Hu","year":"2014","unstructured":"Hu, L. et al. Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine. Biomark. Res. 2, 3 (2014).","journal-title":"Biomark. Res."},{"key":"62506_CR78","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi0889","volume":"9","author":"L Zhong","year":"2023","unstructured":"Zhong, L. et al. Augmenting L3MBTL2-induced condensates suppresses tumor growth in osteosarcoma. Sci. Adv. 9, eadi0889 (2023).","journal-title":"Sci. Adv."},{"key":"62506_CR79","doi-asserted-by":"publisher","first-page":"1713526","DOI":"10.1080\/20013078.2020.1713526","volume":"9","author":"JA Welsh","year":"2020","unstructured":"Welsh, J. A. et al. MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments. J. Extracell. Vesicles 9, 1713526 (2020).","journal-title":"J. Extracell. Vesicles"},{"key":"62506_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12299","volume":"12","author":"JA Welsh","year":"2023","unstructured":"Welsh, J. A. et al. A compendium of single extracellular vesicle flow cytometry. J. Extracell. Vesicles 12, e12299 (2023).","journal-title":"J. Extracell. Vesicles"},{"key":"62506_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/cpcy.81","volume":"95","author":"A Morales-Kastresana","year":"2020","unstructured":"Morales-Kastresana, A., Welsh, J. A. & Jones, J. C. Detection and sorting of extracellular vesicles and viruses using nanoFACS. Curr. Protoc. Cytom. 95, e81 (2020).","journal-title":"Curr. Protoc. Cytom."},{"key":"62506_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57974-3","volume":"14","author":"H Kobayashi","year":"2024","unstructured":"Kobayashi, H. et al. Precise analysis of single small extracellular vesicles using flow cytometry. Sci. Rep. 14, 7465 (2024).","journal-title":"Sci. Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62506-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62506-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62506-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T14:04:26Z","timestamp":1757340266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62506-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62506"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62506-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"29 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7166"}}